Join Growin Stock Community!

Viking therapeutics inc(VKTX.US Overview)

US StockHealthcare
No presentation for VKTX

VKTX AI Insights

VKTX Overall Performance

VKTX AI Analysis & Strategy

VKTX Recent Performance

0.30%

Viking therapeutics inc

-1.38%

Avg of Sector

-1.03%

S&P 500

VKTX PowerScanner

VKTX Key Information

VKTX Valuation Metrics

VKTX Earnings Table

VKTX Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Price of VKTX

VKTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer